Enjoy complimentary customisation on priority with our Enterprise License!
The stem cell umbilical cord blood (UCB) market size is forecast to increase by USD 1.69 billion at a CAGR of 18.5% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of metabolic disorders and the rising demand for advanced transplant medicine. The investment in regenerative medicine is surging, leading to increased research and development in UCB applications.
However, the market faces challenges such as high operational costs, including testing and storage in specialized facilities. These facilities ensure the safety and efficacy of the UCB, which is crucial for successful transplantation. The report provides an in-depth analysis of these trends and challenges, offering insights into the market's future growth prospects.
_Market_size_abstract_2024_v1.jpg?format=webp)
Umbilical cord blood (UCB) is a rich source of hematopoietic stem cells (HSCs), which have the ability to develop into various blood cells. These cells play a crucial role in the formation and maintenance of the hematopoietic system. UCB holds immense potential for clinical applications, particularly in the context of chronic diseases, genetic disorders, and blood illnesses such as leukemia and lymphoma. The isolation and storage of UCB stem cells have gained significant attention in the medical community due to their potential use in regenerative medicines.
Additionally, the biological activities of these cells contribute to tissue development and offer therapeutic benefits for various lifethreatening diseases. Newborn babies provide an abundant source of UCB, which can be collected from the umbilical cord and placenta following birth. UCB storage services have emerged as a vital component of the healthcare industry, allowing for the preservation of these valuable cells for future use. Adult stem cells also exhibit similar regenerative properties, but UCB stem cells offer advantages such as a lower risk of rejection and a more rapid engraftment process. As a result, UCB has become an essential resource for clinical applications, including bone marrow transplants and gene therapies.
Moroever, the commercialization of UCB has been facilitated by advancements in isolation and storage methods. These techniques ensure the preservation of UCB stem cells in optimal conditions, maintaining their viability and potency for potential future use. UCB holds promise for addressing a wide range of conditions, including rare diseases and hematopoietic disorders. The use of UCB in clinical applications continues to expand, driven by ongoing research and advancements in the field. In summary, the UCB market represents a significant opportunity for the healthcare industry, with potential applications in the treatment of various diseases and disorders. The collection, isolation, and storage of UCB stem cells have become essential components of modern medicine, offering hope for patients suffering from life threatening conditions.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The pharmaceutical segment is estimated to witness significant growth during the forecast period. Stem cells, particularly those derived from umbilical cord blood (UCB), hold immense potential in the medical field due to their ability to transform into various cell types. The process of cryopreservation enables the preservation of these valuable cells for future use. The ethical and cultural considerations surrounding their use are topics of ongoing debate. In the US, hospitals and clinics play a crucial role in facilitating the collection and storage of UCB. With over 6,600 active pharmaceutical companies in the country, the presence of a strong healthcare system offers ample opportunities for market growth. Significant investments in stem cell research further underscore the expanding market for UCB. This burgeoning sector is poised to deliver innovative biotechnology solutions, contributing to advancements in disease modeling and therapeutic applications.
_Market_segments_abstract_2024_v2.jpg?format=webp)
Get a glance at the market share of various segments Request Free Sample
The pharmaceutical segment was valued at USD 444.60 million in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
_Market_regions_abstract_2023_geo_v2.jpg?format=webp)
For more insights on the market share of various regions Request Free Sample
In North America, the market is experiencing significant growth due to the region's advanced technological infrastructure and the presence of notable companies like Americord Registry LLC, Global Cord Blood Corp., and Next Biosciences Pty Ltd. These companies offer stem cell storage and processing services, utilizing stem cells to create treatments for diseases such as cancer. The United States and Canada are the primary contributors to the North American market's revenue. The well-established healthcare system in these countries facilitates the entry of biotechnology solution providers into the global stem cell UCB market.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Rising prevalence of several chronic disorders is the key driver of the market. Chronic diseases, including cardiovascular disease, cancer, chronic obstructive pulmonary disease, and type 2 diabetes, are major health concerns worldwide, accounting for a significant percentage of global deaths and disease burden. These conditions are often caused by factors such as unhealthy lifestyles, obesity, and tobacco use. By 2022, it is projected that chronic diseases will be responsible for 72.94% of all deaths and 59.96% of the global disease burden. A considerable number of deaths related to these diseases, approximately 78.92%, occur in developing countries.
Similarly, hematopoietic stem cells derived from umbilical cord blood (UCB) offer potential solutions for treating various chronic and genetic diseases, including rare conditions. Clinical applications of UCB-derived hematopoietic stem cells have shown promising results in the treatment of leukemia, lymphoma, and other blood disorders. As the demand for effective treatments for chronic and genetic diseases continues to grow, the commercialization of UCB-derived stem cell therapies is gaining momentum. The use of UCB in stem cell therapy holds significant potential for improving patient outcomes and quality of life.
Increasing investments in the field of regenerative medicines is the upcoming trend in the market. Stem cells are the fundamental building blocks of the human body, capable of developing into various specialized cell types as needed. Under specific conditions, either within the body or in a laboratory, stem cells multiply, giving rise to new daughter cells. These daughter cells can further differentiate into new stem cells or specialized cells, such as blood, brain, heart muscle, or bone cells. The body does not naturally produce cells with the capacity to generate new cell types.
Additionally, the potential of stem cells has led researchers and medical professionals to explore their use in understanding diseases, generating healthy cells to replace diseased ones, and testing new drugs for safety and efficacy. Stem cell research and applications in regenerative medicine and transplant medicine continue to expand, with an increasing focus on umbilical cord blood (UCB) as a valuable source for stem cells due to its accessibility and richness in stem cells. Storage facilities play a crucial role in preserving the potential of UCB stem cells for future use. Extensive testing and stringent quality control measures are essential to ensure the safety and efficacy of UCB-derived stem cells for various therapeutic applications.
High operational costs are the key challenges affecting market growth. The market is experiencing growth due to the increasing demand for advanced therapeutics for various conditions, including cancer, diabetes, and blood diseases, as well as immune disorders. However, the market is hindered by the substantial expenses related to storing and processing stem cells. These costs are a significant obstacle for patients and pose a challenge for new entrants in the market.
However, private cord blood banks, in particular, carry a high price tag. For instance, the initial fee for private cord blood banking ranges from USD 1,000 to USD 2,000, with an annual storage fee exceeding USD100 for the duration of storage. Americord, a US-based private cord blood bank, offers a costly payment structure, which includes a one-time fee for 20 years of storage. These financial hurdles necessitate careful consideration and planning for individuals and families seeking to invest in stem cell UCB services.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
_Market_customer_landscape_abstract_2023_geo_v1.jpg?format=webp)
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Americord Registry LLC: The company offers stem cell UCB products such as Cord Blood 2.0.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Stem cells derived from umbilical cord blood (UCB) have emerged as a promising solution for various clinical applications, particularly in the treatment of chronic and genetic diseases, blood illnesses, immune disorders, metabolic disorders, cancer, diabetes, and rare diseases. The therapeutic potential of hematopoietic stem cells present in UCB has led to their commercialization in the form of stem cell banks and storage services. The global market for UCB is growing rapidly due to the increasing demand for regenerative medicines and transplant medicine. UCB storage facilities offer testing and storage services, ensuring the preservation of these valuable cells for future use.
However, hybrid storage services combine cryopreservation and testing, providing an added layer of security and convenience. Policies and ethical issues surrounding UCB collection and storage continue to evolve, with hospitals and clinics playing a crucial role in raising awareness and facilitating access to these services. The use of UCB in the treatment of lifethreatening diseases, such as leukaemia and lymphoma, has been well-documented, highlighting the importance of UCB as a valuable resource in the field of medicine. Adult stem cells and their biological activities in tissue development have also gained significant attention, expanding the potential applications of UCB in regenerative medicine. The private UCB banks play a vital role in ensuring the availability of these precious cells for individuals and families, offering peace of mind and hope for those facing the challenges of serious diseases.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
137 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 18.5% |
|
Market growth 2024-2028 |
USD 1.69 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
15.2 |
|
Regional analysis |
North America, Asia, Europe, and Rest of World (ROW) |
|
Performing market contribution |
North America at 40% |
|
Key countries |
US, China, Germany, UK, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Americord Registry LLC, Athersys Inc., CBR Systems Inc., Cells4Life Group LLP, Celularity Inc., Cordlife Group Ltd., CRYO-CELL International Inc, Cryo Stemcell, Cryoviva Biotech Pvt. Ltd., FamiCord Group, FUTURE CELL Japan, Global Cord Blood Corp., LifeCell International Pvt. Ltd., MEDIPOST Co. Ltd., Next Biosciences Pty Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Smith and Nephew plc, ViaCord LLC, and Vita 34 AG |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
